Compare McKesson Corporation (MCK) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Visa Inc — how do they compare? McKesson Corporation trades at $899.06 (market cap $102.58B), while Visa Inc trades at $362.79 (market cap $668.96B). The key difference: Visa Inc is far larger — about 6.5× McKesson Corporation's market cap, and Visa Inc pays the higher dividend (0.74%). Which is the better fit depends on your goals.
| MCK | V | |
|---|---|---|
Market Cap | $102.58B | $668.96B |
Sector | Health | Financials |
52-Week High | $995.69 | $370.47 |
52-Week Low | $659.01 | $295.52 |
Enterprise Value | $109.12B | $679.54B |
Dividend Yield | 0.43% | 0.74% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
Visa (V) trades at $361.32, down 0.33% on the day, with strong fundamentals including 50.78% net income margin and consistent earnings beats. The stock shows bearish technical signals but maintains bullish moving averages. Recent developments include AI-powered commerce initiatives and stablecoin partnerships, positioning Visa for future payment system evolution. Financial trends show revenue growth from $29.3B in 2022 to $40B in 2025, with robust cash flow generation.
Visa presents a compelling long-term investment with 85% analyst buy ratings and $426.31 consensus price target suggesting 18% upside. Key risks include fintech competition and regulatory pressures, but the company's dominant market position, high profitability, and innovation in digital payments support continued growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
